Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis
6 affiliations
- 1Department of Biotechnology and Genetic Engineering, Jahangirnagar University, Dhaka, Bangladesh.
- 2Department of Biochemistry and Molecular Biology, Jahangirnagar University, Dhaka, Bangladesh.
- 3Department of Biochemistry and Biotechnology, School of Health and Life Sciences, North South University, Dhaka, Bangladesh.
- 4Department of Zoology, Government City College, Chattogram, Bangladesh.
- 5Department of Biochemistry and Microbiology, North South University, Dhaka, Bangladesh.
- 6Department of Microbiology, Notre Dame University Bangladesh (NDUB), Dhaka, Bangladesh.
Abstract
Marburg virus disease (MVD), a deadly zoonotic illness in humans, is caused by the Marburg virus (MARV), a single-stranded RNA virus belonging to the Orthomarburgvirus genus of the Filoviridae family. There are currently no approved vaccines or efficient antiviral therapies for MARV, despite high morbidity and fatality rates of the virus, particularly in Africa. Recognizing its epidemic potential and its inclusion on the WHO list of blueprint priority pathogens, an immunoinformatics approach was used to design novel multi-epitope saRNA vaccine candidates (MB-saVaxI and MB-saVaxII) targeting the viral GP, NP, VP40, and VP35 via CD8 + , CD4 + , and B cell epitopes. These epitopes were derived from target protein sequences and incorporated into MB-saVaxI and MB-saVaxII after validation for antigenicity, non-allergenicity, non-toxicity, and conservation. Additionally, the selected epitopes were conjugated to suitable adjuvants via various linkers, thereby enabling the design of a potentially stable vaccine. Additionally, the designed MB-saVaxI and MB-saVaxII were incorporated into the standard saRNA model, in which ORF-2 encodes the target vaccine peptide. Moreover, biophysical analyses unveiled that the developed vaccines are basic (pI < 7), soluble (GRAVY < 0), and stable (aliphatic index < 80). Subsequently, docking of MB-saVaxI to TLR2 (−938.3) and TLR4 (−902.4), and MB-saVaxII to TLR3 (−1485.4) and TLR7 (−1543.6) demonstrated significant affinity, with detailed hydrogen-bond interactions validated by MM-GBSA and molecular dynamics simulations. Furthermore, MB-saVaxI and MB-saVaxII were effectively cloned in-silico into Escherichia coli, and immune simulations indicated that the vaccines triggered robust innate and adaptive immunity, with a sustained memory response and TH cell activation, as evidenced by IFN-γ and IL-2 production. Additionally, the mRNA structure of MB-saVaxI and MB-saVaxII remained stable throughout the expression pathway in the host. However, extensive in-vitro and in-vivo studies are needed to establish the safety and efficacy of this vaccine candidate conclusively.
Related
- An immunoinformatics-driven multiepitope subunit vaccine targeting Oropouche virus: Molecular docking, immune and dynamics simulation approaches
- AI-Driven Design of Next-Generation Immunoinformatics Multi-Epitope Subunit Vaccine Targeting the Most Virulent Mpox Proteome: A Structural and Kinetic Validation Framework
- SemVac: A Semantic Vaccinology Paradigm Powered by LLMs for Antigen Discovery
- Computational prediction of a multi-epitope Human Metapneumovirus vaccine candidate through integrated reverse vaccinology and pan-genomic approaches
- Reverse vaccinology for development of vaccine against Aeromonas hydrophila infection in nile tilapia (Oreochromis niloticus).
BibTeX
@article{rahman2026immunoinformatics,
title = {{Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis}},
author = {Md Aftabur Rahman and Lamyea Kabir and Nadia Ahmed and Atish Barua and Mohammad Hasan and Ahmad Abdullah Mahdeen},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0361136},
url = {https://doi.org/10.1371/journal.pone.0361136},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immunoinformatics and reverse vaccinology design of self-amplifying RNA vaccine against marburg virus with structural dynamics and immune simulation analysis
AU - Md Aftabur Rahman
AU - Lamyea Kabir
AU - Nadia Ahmed
AU - Atish Barua
AU - Mohammad Hasan
AU - Ahmad Abdullah Mahdeen
PY - 2026
DA - 2026/10/23
JO - PLOS One
DO - 10.1371/journal.pone.0361136
UR - https://doi.org/10.1371/journal.pone.0361136
AB - Marburg virus disease (MVD), a deadly zoonotic illness in humans, is caused by the Marburg virus (MARV), a single-stranded RNA virus belonging to the Orthomarburgvirus genus of the Filoviridae family. There are currently no approved vaccines or efficient antiviral therapies for MARV, despite high morbidity and fatality rates of the virus, particularly in Africa. Recognizing its epidemic potential and its inclusion on the WHO list of blueprint priority pathogens, an immunoinformatics approach was used to design novel multi-epitope saRNA vaccine candidates (MB-saVaxI and MB-saVaxII) targeting the viral GP, NP, VP40, and VP35 via CD8 + , CD4 + , and B cell epitopes. These epitopes were derived from target protein sequences and incorporated into MB-saVaxI and MB-saVaxII after validation for antigenicity, non-allergenicity, non-toxicity, and conservation. Additionally, the selected epitopes were conjugated to suitable adjuvants via various linkers, thereby enabling the design of a potentially stable vaccine. Additionally, the designed MB-saVaxI and MB-saVaxII were incorporated into the standard saRNA model, in which ORF-2 encodes the target vaccine peptide. Moreover, biophysical analyses unveiled that the developed vaccines are basic (pI < 7), soluble (GRAVY < 0), and stable (aliphatic index < 80). Subsequently, docking of MB-saVaxI to TLR2 (−938.3) and TLR4 (−902.4), and MB-saVaxII to TLR3 (−1485.4) and TLR7 (−1543.6) demonstrated significant affinity, with detailed hydrogen-bond interactions validated by MM-GBSA and molecular dynamics simulations. Furthermore, MB-saVaxI and MB-saVaxII were effectively cloned in-silico into Escherichia coli, and immune simulations indicated that the vaccines triggered robust innate and adaptive immunity, with a sustained memory response and TH cell activation, as evidenced by IFN-γ and IL-2 production. Additionally, the mRNA structure of MB-saVaxI and MB-saVaxII remained stable throughout the expression pathway in the host. However, extensive in-vitro and in-vivo studies are needed to establish the safety and efficacy of this vaccine candidate conclusively.
SN - 1932-6203
ER -